Gastrointestinal Bleeding with Dabigatran, a Comparative Study with Warfarin: A Multicenter Experience / 대한소화기학회지

ABSTRACT

BACKGROUND/AIMS: The risk of gastrointestinal (GI) bleeding with dabigatran when compared to warfarin has been controversial in the literature. The aim of our study was to assess this risk with the use of dabigatran. METHODS: We examined the medical records of patients who were started on dabigatran or warfarin from October 2010 to October 2012. The study was conducted in two hospitals. RESULTS: A total of 417 patients were included (208 dabigatran vs. 209 warfarin). GI bleeding occurred in 10 patients (4.8%) in the dabigatran group compared to 21 patients (10.1%) in the warfarin group (p=0.0375). Multivariate analysis showed that patients who were on dabigatran for 100 days (p=0.0007). The odds of GI bleeding in patients who were on dabigatran for 100 days. The incidence of GI bleeding in patients >65 years old was higher than in those 65 years, and a history of previous GI bleeding.